Background Reaching the therapeutic target of remission or low-disease activity has
improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target …

Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about
their application in the real world. With many products coming to market and a wealth of …

Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …

Introduction: South Africa has an appreciable burden of both communicable and non-
communicable diseases as well as high maternal, neonatal, and child morbidity. In recent …

Rheumatoid arthritis (RA) is a chronic inflammatory disease which, if left untreated, leads to
functional disability, pain, reduced health-related quality of life and premature mortality …

Biological therapies are an effective treatment for a range of immune-mediated inflammatory
diseases (IMIDs), including rheumatoid arthritis, psoriasis, and inflammatory bowel …

Background and objectives The 52‐week, randomized, double‐blind, noninferiority,
government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab …

Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

Objectives Efficacy, safety and immunogenicity results from the phase III study of SB2, a
biosimilar of reference infliximab (INF), were previously reported through 54 weeks. This …

Importance Among patients with rheumatoid arthritis (RA) who had an inadequate response
to methotrexate, a treatment sequence initiated with biosimilar disease-modifying …